Valve replacement for appetite suppressant-induced valvular heart disease

Shankha S. Biswas, Carolyn L. Donovan, Joseph M. Forbess, Stephen H. Royal, Kevin P. Landolfo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Valvular heart disease associated with the use of appetite-suppressant medication is a recently described clinical entity. Although the mechanism of valvular injury remains elusive pathologically, the valvular abnormalities resemble those observed in carcinoid syndrome. The incidence of clinically evident valvular heart disease is low with short-term (less than 3 months) exposure to appetite-suppressant drugs. Prolonged exposure to higher doses in addition to combination drug therapy confers an excess risk for valvular pathologic changes. We report the case of a patient with severe mitral, regurgitation who had short-term exposure (3 weeks) to the combination of fenfluramine (20 mg) and phenteramine (15 mg).

Original languageEnglish (US)
Pages (from-to)1819-1822
Number of pages4
JournalAnnals of Thoracic Surgery
Volume67
Issue number6
DOIs
StatePublished - Jun 1999

Fingerprint

Appetite Depressants
Heart Valve Diseases
Fenfluramine
Carcinoid Tumor
Mitral Valve Insufficiency
Combination Drug Therapy
Incidence
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Valve replacement for appetite suppressant-induced valvular heart disease. / Biswas, Shankha S.; Donovan, Carolyn L.; Forbess, Joseph M.; Royal, Stephen H.; Landolfo, Kevin P.

In: Annals of Thoracic Surgery, Vol. 67, No. 6, 06.1999, p. 1819-1822.

Research output: Contribution to journalArticle

Biswas, Shankha S. ; Donovan, Carolyn L. ; Forbess, Joseph M. ; Royal, Stephen H. ; Landolfo, Kevin P. / Valve replacement for appetite suppressant-induced valvular heart disease. In: Annals of Thoracic Surgery. 1999 ; Vol. 67, No. 6. pp. 1819-1822.
@article{c786a483738b4b058c5b6ce38375b091,
title = "Valve replacement for appetite suppressant-induced valvular heart disease",
abstract = "Valvular heart disease associated with the use of appetite-suppressant medication is a recently described clinical entity. Although the mechanism of valvular injury remains elusive pathologically, the valvular abnormalities resemble those observed in carcinoid syndrome. The incidence of clinically evident valvular heart disease is low with short-term (less than 3 months) exposure to appetite-suppressant drugs. Prolonged exposure to higher doses in addition to combination drug therapy confers an excess risk for valvular pathologic changes. We report the case of a patient with severe mitral, regurgitation who had short-term exposure (3 weeks) to the combination of fenfluramine (20 mg) and phenteramine (15 mg).",
author = "Biswas, {Shankha S.} and Donovan, {Carolyn L.} and Forbess, {Joseph M.} and Royal, {Stephen H.} and Landolfo, {Kevin P.}",
year = "1999",
month = "6",
doi = "10.1016/S0003-4975(99)00328-8",
language = "English (US)",
volume = "67",
pages = "1819--1822",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Valve replacement for appetite suppressant-induced valvular heart disease

AU - Biswas, Shankha S.

AU - Donovan, Carolyn L.

AU - Forbess, Joseph M.

AU - Royal, Stephen H.

AU - Landolfo, Kevin P.

PY - 1999/6

Y1 - 1999/6

N2 - Valvular heart disease associated with the use of appetite-suppressant medication is a recently described clinical entity. Although the mechanism of valvular injury remains elusive pathologically, the valvular abnormalities resemble those observed in carcinoid syndrome. The incidence of clinically evident valvular heart disease is low with short-term (less than 3 months) exposure to appetite-suppressant drugs. Prolonged exposure to higher doses in addition to combination drug therapy confers an excess risk for valvular pathologic changes. We report the case of a patient with severe mitral, regurgitation who had short-term exposure (3 weeks) to the combination of fenfluramine (20 mg) and phenteramine (15 mg).

AB - Valvular heart disease associated with the use of appetite-suppressant medication is a recently described clinical entity. Although the mechanism of valvular injury remains elusive pathologically, the valvular abnormalities resemble those observed in carcinoid syndrome. The incidence of clinically evident valvular heart disease is low with short-term (less than 3 months) exposure to appetite-suppressant drugs. Prolonged exposure to higher doses in addition to combination drug therapy confers an excess risk for valvular pathologic changes. We report the case of a patient with severe mitral, regurgitation who had short-term exposure (3 weeks) to the combination of fenfluramine (20 mg) and phenteramine (15 mg).

UR - http://www.scopus.com/inward/record.url?scp=0033067141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033067141&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(99)00328-8

DO - 10.1016/S0003-4975(99)00328-8

M3 - Article

VL - 67

SP - 1819

EP - 1822

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -